0001209191-23-053670.txt : 20231026 0001209191-23-053670.hdr.sgml : 20231026 20231026164606 ACCESSION NUMBER: 0001209191-23-053670 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231024 FILED AS OF DATE: 20231026 DATE AS OF CHANGE: 20231026 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Thiara Parvinder CENTRAL INDEX KEY: 0001995535 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40384 FILM NUMBER: 231350804 MAIL ADDRESS: STREET 1: C/O TOURMALINE BIO, INC. STREET 2: 27 WEST 24TH STREET, SUITE 702 CITY: NEW YORK STATE: NY ZIP: 10010 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Tourmaline Bio, Inc. CENTRAL INDEX KEY: 0001827506 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 27 WEST 24TH STREET STREET 2: SUITE 702 CITY: NEW YORK STATE: NY ZIP: 10010 BUSINESS PHONE: 646-481-9832 MAIL ADDRESS: STREET 1: 27 WEST 24TH STREET STREET 2: SUITE 702 CITY: NEW YORK STATE: NY ZIP: 10010 FORMER COMPANY: FORMER CONFORMED NAME: Talaris Therapeutics, Inc. DATE OF NAME CHANGE: 20201007 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-10-24 0 0001827506 Tourmaline Bio, Inc. TRML 0001995535 Thiara Parvinder C/O TOURMALINE BIO, INC. 27 WEST 24TH STREET, SUITE 702 NEW YORK NY 10010 1 0 0 0 0 Common Stock 2023-10-24 4 P 0 5000 10.66 A 80782 D Common Stock 2023-10-25 4 P 0 2000 12.12 A 82782 D The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.13 to $10.86 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.95 to $12.28 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. /s/ Brad Middlekauff, Attorney-in-Fact 2023-10-26